Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 2.50 -0.02 (-0.79%)
price chart
Pluristem Therapeutics Inc.'s PLX Cells Get Green Light For Fast Track ...
Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, it appears the fantasy may become reality, featuring Pluristem Therapeutics Inc. (NASDAQ:PSTI) as its ...
Pluristem Therapeutics's Buy Rating Reiterated at Maxim Group (PSTI)  The Legacy
New Rochelle, NY  The Daily Voice
Pluristem Therapeutics Announces Pricing of Registered Direct Offering of ...
Pluristem Therapeutics Inc. PSTI, -1.17% (tase:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common stock and warrants to purchase up to 4,080,000 shares of common stock at a combined price of $2.50 ...
Pluristem Therapeutics, Inc. Short Interest Update
Pluristem Therapeutics, Inc. (NASDAQ:PSTI), A rise of 72,647 shares or 8.3% was seen in the short interest of Pluristem Therapeutics, Inc.. Even as the interest increased from 879,247 shares on May 29,2015 to 951,894 shares on June 15,2015, the days to ...
Zacks Short Term Rating on Pluristem Therapeutics, Inc. (NASDAQ:PSTI)
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) remains a strong buy in the latest set of rankings. The Shares has received an average rating of 1 by 3 analysts.
Fast Moving Stocks: Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Sprint ...  Stock Transcript
High Velocity Stocks: Ericsson (NASDAQ:ERIC), Google Inc (NASDAQ:GOOG ...  Property Mentor
Pluristem Therapeutics Inc.: Pluristem Granted Australian Patent for 3D Cell ...
HAIFA, ISRAEL, June 24, 2015 --Pluristem Therapeutics Inc . (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that it has been granted an Australian patent titled "Adherent Cells From Placenta ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Analyst Rating Update
Pluristem Therapeutics, Inc. (NASDAQ:PSTI): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $6 in Pluristem Therapeutics, Inc. (NASDAQ:PSTI). However, the stock price could fluctuate by $ 2.83 from the ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a Buy: MLV & Co
In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI). The analyst placed a $6.00 price target on the stock which indicates a 105.48% upside to the last closing price.
MLV Maintains Buy on Pluristem Therapeutics Inc. as PLX-R18 Strategy ...
In a research report published Tuesday, MLV analyst Vernon Bernardino maintained a Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a price target of $6.00, which represents a potential upside of 113% from where the stock is currently ...
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Pluristem Therapeutics (PSTI) Reports Data from Phase I/II PLX-PAD Trail  StreetInsider.com
Pluristem Announces Significant New Finding From Its Phase I/II Muscle ...  GlobeNewswire (press release)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.